Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by IFP Advisors Inc

IFP Advisors Inc lifted its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 96.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,777 shares of the biopharmaceutical company's stock after purchasing an additional 2,348 shares during the period. IFP Advisors Inc's holdings in Intra-Cellular Therapies were worth $399,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wealthspire Advisors LLC acquired a new stake in Intra-Cellular Therapies in the fourth quarter valued at approximately $219,000. ING Groep NV purchased a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $1,044,000. Handelsbanken Fonder AB raised its holdings in shares of Intra-Cellular Therapies by 3.0% in the 4th quarter. Handelsbanken Fonder AB now owns 27,100 shares of the biopharmaceutical company's stock valued at $2,263,000 after purchasing an additional 800 shares in the last quarter. Ieq Capital LLC lifted its position in shares of Intra-Cellular Therapies by 469.4% during the 4th quarter. Ieq Capital LLC now owns 32,398 shares of the biopharmaceutical company's stock worth $2,706,000 after purchasing an additional 26,708 shares during the last quarter. Finally, TimesSquare Capital Management LLC grew its stake in shares of Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company's stock worth $70,179,000 after purchasing an additional 402,186 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the company's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Stock Performance

Intra-Cellular Therapies stock traded up $3.08 during midday trading on Monday, hitting $131.28. 7,155,386 shares of the company's stock were exchanged, compared to its average volume of 3,931,705. The stock has a market cap of $13.96 billion, a price-to-earnings ratio of -150.89 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 12-month low of $63.30 and a 12-month high of $131.35. The firm's 50 day simple moving average is $114.58 and its 200 day simple moving average is $91.72.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. On average, equities research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of analyst reports. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. JPMorgan Chase & Co. upped their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an "overweight" rating in a report on Monday, November 4th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Piper Sandler restated a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.